CME CirclePrint this Activity for Offline ReferenceInstructions on Taking Medscape CME

The Role of Anti-Aromatase Agents in New Treatment Strategies for Breast Cancer CME
Chairperson: Gabriel N. Hortobagyi, MD, FACP; Faculty: Paul E. Goss, MD, PhD, FRCPC, FRCP; William J. Gradishar, MD; Joanne E. Mortimer, MD; Victor G. Vogel, MD, MHS
Disclosures

Release Date: March 26, 2003; Valid for credit through March 26, 2004

This activity has expired.
CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities.


This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Role of Anti-Aromatase Agents in New Treatment Strategies for Breast Cancer" satellite symposium held at the Marion Koogler McNay Art Museum in San Antonio, Texas on December 11, 2002.

Contents of This CME Activity
This program is offered in two formats. Please choose one of the versions:

    Flash Version
    (A multimedia presentation with synchronized audio, slides and transcript.)
    Note: Macromedia's Flash Player 5 plug-in is required to view the Flash version.
    Download the Macromedia Flash Player 5 plug-In:

    Get Flash 5

    --OR--

    Slides with transcript and RealAudio:

  1. Current Options in Hormonal Therapy
    About Endocrine Therapies
    Use of Aromatase Inhibitors
    The Estrogen Receptor Downregulators
    The Sequence of Endocrine Treatments Today
    Adjuvant Endocrine Therapy
    Prevention of Breast Cancer

  2. Sequencing the Aromatase Inhibitors: Does it Make a Difference?
    Types of Endocrine Therapies and Goals of Treatment
    Potential Sequences for Endocrine Therapies
    Conclusions

  3. Implications of Anti-Aromatase Structural Differences
    Aromatase Inhibitors and Inactivators
    Are the Nonsteroidal Aromatase Inhibitors Equivalent?
    Estrogen Suppression and the Aromatase Inhibitors: Is There a Difference?
    Are There Advantages With One Aromatase Inhibitor Over Another?
    Can Patients Go From Class to Class?
    Adverse Effects and Effects on Bone Among Agents?
    Conclusions

  4. Moving Anti-Aromatase Agents in to the Adjuvant Setting
    Aromatase Inhibition in the Adjuvant Setting
    Adjuvant Anastrozole: The Arimidex (Anastrozole) and Tamoxifen Alone or in Combination (ATAC) Trial
    Additional Adjuvant Therapy Trials
    Aromatase Inhibitors: Effects on Lipids and Bone
    Aromatase Inhibitors in the Adjuvant Setting? Findings From the American Society of Clinical Oncology
    Conclusions

  5. Prevention Strategies with Anti-Aromatase Agents
    Aromatase Inhibition in Breast Cancer Prevention
    Findings From ATAC -- The Trial of Anastrozole and Tamoxifen Alone or in Combination
    The Use of Exemestane
    Combination Therapy With Cyclooxygenase-2 Inhibitors
    Clinical Strategies: Adjuvant Breast Cancer Trials
    Clinical Strategies: Phase II Surrogate Endpoint Studies
    Clinical Strategies: Phase III Clinical Outcome Trials

These educational activities, certified by accredited providers, were not prepared by Medscape's editors, but are made available on our site as a service to our audience. Authors are routinely instructed by the provider to disclose significant financial relationships and mention of investigational drugs and unapproved indications. Medscape has received a fee for posting these activities. Direct questions or comments to: CME@webmd.net.

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape, Seton Hall University School of Graduate Medical Education, the companies providing educational grants or the authors and writers. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information and consult a qualified healthcare professional before treating patients or utilizing any therapeutic product discussed in this educational activity.

 
Copyright © 2003 Clinical Insights, Inc.
Pharmacia Oncology
  • This activity has expired.

    The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.

  • CME Information
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.